Genitourinary Cancer

EDU 23 - (INTERACTIVE) Ultra-hypofractionated Therapy for Clinically Localized Prostate: Are We Finally Ready for Prime Time?

10/23/2018
1:00 PM - 2:30 PM
Location: Room 214 A/B

Session Type: Educational
1.50 AMA PRA Category 1 Credits™
1.50 CAMPEP Credits
1.50 MDCB Credits

This session will represent a comprensive overview of the role of SBRT in the management of clinically localized prostate cancer. The session will highlight the tumor control outcomes and toxicity based on published data and compare these outcomes to what is observed with standard radiotherapeutic interventions. Focus will also be given to technical and treatment planning aspects of therapy as well as important selection criteria that are associated with achieving reduced toxicity after therapy. The session will also discuss specific issues regarding SBRT including optimal dosing and role of SBRT in higher risk disease.The session will provide a balanced perspective of the clinical advantages and disadvantages of SBRT. Finally a panel discussion will be included which will focus on how we educate our patients regarding the role of SBRT and how to follow patients after therapy to evaluate tumor response and detection of recurrence.

Learning Objectives:

Presentations:

Michael Zelefsky, MD

Memorial Sloan Kettering Cancer Center

Disclosure:
Employment
Memorial Sloan-Kettering Cancer Center: Attending Physician: Employee

Compensation
Alpha Tau- Radiopharmaceuticals: Consultant; Augmenix: Consultant; Consultant: Consultant

Presentation(s):

Send Email for Michael Zelefsky


Assets

EDU 23 - (INTERACTIVE) Ultra-hypofractionated Therapy for Clinically Localized Prostate: Are We Finally Ready for Prime Time?



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for EDU 23 - (INTERACTIVE) Ultra-hypofractionated Therapy for Clinically Localized Prostate: Are We Finally Ready for Prime Time?